胰腺癌患者血清中CA199、CA242、CA125、CEA检测分析

摘要

目的 探讨血清肿瘤标志物CA19-9、CA242、CA125、CEA检测在胰腺癌诊断及疗效监测的价值.方法 用多肿瘤标志物蛋白芯片诊断系统测定87例胰腺炎患者、1150例健康体检者(对照组)、133例胰腺癌患者,及30例胰腺癌患者手术前后血清中CA199、CA242、CA125、CEA含量.结果 肿瘤标志物CA199、CA242、CA125、CEA胰腺癌组的阳性率为84.9%,炎症组阳性率为38.7%,正常对照组阳性率为1.6%,胰腺癌组阳性率显著高于胰腺炎组和健康体检对照组(P＜0.01).胰腺癌患者手术前4项肿瘤标志物的水平表达高于手术后(P＜0.05).结论 联合检测血清CA199、CA242、CA125、CEA水平对胰腺癌辅助诊断有较好的临床参考价值.%Objective To discuss the diagnostic and therapeutic effect monitoring value of detecting serum tumormarkrer,CA199 ,CA242 ,CA125 ,CEA in pancreatic cancer. Methods CA19-9 ,CA242 ,CA125 ,CEA of 133 patients of pancreatic cancer,30 cases of preoperation and postoperation ,87 pancreatitis are detected by Multi-Tumor Markers Protein Biochip Diagnosis System ,1150 health exam inates as the control group .Results The positive ratio of pancreatic cancer group is 84.9％ ,much m ore than it of pancreatitis (38.7％) and health exam inates (1.6％), P＜0.01 .The concentrations of the four markers in the cases of preoperation are higherthan that of postoperation, P＜0.05 .Conclusion Detecting serum tumormarker,CA19-9 ,CA242 ,CA125 ,CEA simultaneously has better clinical value in auxiliary diagnosis of pancreatic cancer.